D. Boral Capital Reiterates “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $3.00 target price on the stock.

VNRX has been the topic of a number of other reports. HC Wainwright reduced their price target on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a report on Monday, November 17th. Maxim Group downgraded VolitionRx from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $2.50.

VolitionRx Stock Performance

NYSE VNRX opened at $0.33 on Friday. VolitionRx has a fifty-two week low of $0.22 and a fifty-two week high of $0.94. The company has a market capitalization of $40.89 million, a PE ratio of -0.92 and a beta of 1.23. The business’s fifty day moving average is $0.31 and its 200 day moving average is $0.52.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes acquired 96,153 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The stock was bought at an average price of $0.51 per share, for a total transaction of $49,038.03. Following the acquisition, the director directly owned 1,062,967 shares in the company, valued at $542,113.17. The trade was a 9.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Cameron John Reynolds acquired 110,000 shares of the business’s stock in a transaction on Tuesday, October 14th. The stock was acquired at an average cost of $0.51 per share, for a total transaction of $56,100.00. Following the transaction, the chief executive officer directly owned 2,534,847 shares in the company, valued at $1,292,771.97. The trade was a 4.54% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 274,229 shares of company stock worth $136,657. Company insiders own 10.40% of the company’s stock.

Institutional Trading of VolitionRx

Institutional investors and hedge funds have recently made changes to their positions in the business. Silverberg Bernstein Capital Management LLC grew its holdings in shares of VolitionRx by 15.6% in the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after purchasing an additional 31,300 shares during the last quarter. Blair William & Co. IL purchased a new stake in VolitionRx in the 2nd quarter valued at about $30,000. Virtu Financial LLC bought a new position in VolitionRx in the 3rd quarter worth about $28,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRx in the 2nd quarter worth about $52,000. Finally, Citadel Advisors LLC increased its position in shares of VolitionRx by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after acquiring an additional 135,775 shares during the period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.